Baader Bank Aktiengesellschaft Decreases Stock Position in Gilead Sciences, Inc. $GILD

Baader Bank Aktiengesellschaft cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,667 shares of the biopharmaceutical company’s stock after selling 1,451 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Gilead Sciences were worth $1,252,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ariel Investments LLC raised its stake in Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after buying an additional 30,630 shares in the last quarter. Golden State Wealth Management LLC raised its stake in Gilead Sciences by 14.5% in the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock valued at $97,000 after buying an additional 109 shares in the last quarter. Swedbank AB raised its stake in Gilead Sciences by 0.8% in the first quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company’s stock valued at $237,393,000 after buying an additional 16,663 shares in the last quarter. ASR Vermogensbeheer N.V. acquired a new stake in Gilead Sciences in the first quarter valued at $11,688,000. Finally, Wealth Enhancement Advisory Services LLC raised its stake in Gilead Sciences by 4.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 292,966 shares of the biopharmaceutical company’s stock valued at $32,827,000 after buying an additional 13,194 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research analyst reports. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Rothschild & Co Redburn lifted their price objective on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. Finally, Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a report on Tuesday, August 19th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $117.17.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $112.26 on Thursday. The stock has a market capitalization of $139.29 billion, a price-to-earnings ratio of 22.36, a PEG ratio of 0.75 and a beta of 0.36. Gilead Sciences, Inc. has a one year low of $81.83 and a one year high of $121.83. The company’s 50-day simple moving average is $114.03 and its 200-day simple moving average is $110.08. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the prior year, the business earned $2.01 earnings per share. Gilead Sciences’s quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the sale, the chief executive officer directly owned 595,725 shares in the company, valued at approximately $67,692,231.75. This trade represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $9,390,030 over the last ninety days. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.